

A Comprehensive Review of Transdermal Patch Delivery Systems

Purva Khatu¹, Divya Torne², Prof. Vaishali Pardeshi³

Department of Quality Assurance^{1,2,3}

Abhinav Education Society's College of Pharmacy, Narhe, Pune, India

Abstract: *In order to overcome the difficulties associated with administering medication, especially orally, the application of medication transdermal administration technique was developed. Transdermal patches are an a sticky a medication-infused patch and put to the skin to provide a certain quantity delivering medicine transdermally entering the blood. It promotes the recuperation process when a body part is injured. By using a membrane that is permeable to cover a supply of medicine or by liquefying small layers of drugs imbedded within the glue with body heat transdermal application allows for a managed delivery of medicine to the individual. One advantages of transdermal medicine delivery above alternative kinds of administration, like current, i.v., and i.m., or oral, is that the remedy offers a regulated The medication's release.*

Keywords: TDDS, Transdermal patches, Skin, Matrix, Reservoir, Systemic circulation, routes of penetration

I. INTRODUCTION

Reducing adverse effects and achieving desired therapeutic benefits is the aim of pharmaceutical research^[1]. Numerous methods of administration, including oral, sublingual, rectum, intramuscular, intravascular, subcutaneous, inhalation, and others, are created to accomplish this purpose. To cure a variety of diseases and ailments, the dose form is administered via the channel of administration given into the body. The various ways of administration have a substantial impact on the body's ability to absorb the active medicine. In the pharmacy, a drug's mode of administration refers to how it enters the body^[2]. Despite being the most popular transport mode, oral medication has some disadvantages due to gastrointestinal Enzymes, pH, and other factors, such as first-pass metabolism and drug degradation. To solve these problems, Chien (1992), and Guy (1996), Banker (1990), it was a transdermal application or transdermal delivery device. Adhesive medication patches are placed to the epidermis in this manner to deliver therapeutically appropriate pharmaceutical doses^[3]. They have numerous ingredients and come in a range of sizes. When applied to undamaged skin, they pierce skin barriers to release active chemicals into the systemic circulation. A transdermal patch designed to provide a high-dosage, long-lasting drug to the skin that diffuses into the bloodstream. There are three ways that medicines can enter the skin: a) via sebaceous glands (b) via hair follicles (C) through an air vent. Transdermal medicine transport devices apply to treat pain, angina pectoris, neurological diseases like Parkinson's disease, and quitting smoking, in addition to a range of skin conditions^[4]

The application of transdermal drugs to the skin

The biggest One of the body's organs is the skin. Though Yes, it is a masterpiece of architecture, the skin usually receives relatively little regard from its occupants. It weighs 4-5 kg, or 9-11 pounds, includes the entire body, and makes up around 7% of an average adult's total body weight. Its surface area is 1.2-2.2 m². The breadth of the skin scale from 1.5 to 4.0 mm. The In addition to being a metabolic organ with synthesizing, excretory, and absorptive functions, skin also serves as a sense organ. It serves as a barrier of defense against the outside world and regulates temperature significantly^[5]




Fig 1: Diagram of skin.

Functions of skin:

Another name for it is the integumentary system, which literally translates to "covering." The skin performs much more than just act as a big, opaque container for bodily fluids.

1. Because it maintains water and other valuable molecules in the body, it is critically necessary. It is also a miracle at preserving water out of the skin's structure.
2. It shields the whole body made of mechanical harm UV rays, chemical damage (from acid and base), and bumps and cuts, sunshine, and microorganisms. It also cushions and insulates the body's deeper organs.
3. Sensation: They skin has a large number of nerve endings and receptors that sense pain, pressure, temperature, and other stimuli.
4. Body temperature regulation: Sweat evaporating from the exterior of the skin return a higher-than-normal the temperature of the body in reaction excessive temperatures or vigorous workout. Alterations in the blood supply to the skin further aid in controlling body condition .
5. Resistance : It transfers immunological data acquired when processing antigens to the relevant lymphatic tissue effector cells.
6. Excretion: Sweat, sebaceous secretions, and apocrine gland secretions are exocrine secretions that facilitate excretion. These excretory secretions are being used to identify specific blood disorders.[6]

Transdermal drug delivery system or (TDDS) :

They seems to exist a painless method of delivering medication to the circulation throughout the body when applied to unbroken skin. Research and interest in the area of transdermal delivery have rapidly increased [5] When applied to intact skin, a discrete dose form that is self-contained is the transdermal medication delivery system that delivers the medication to the circulatory system at a controlled pace by way of the skin [6] methods for delivering drugs applied topically the TDDS, sometimes Called as patches, these types of dosing are meant to distribute a medicinal efficient quantity of medication into the skin of the patient. An advantage over injectables and oral methods is transdermal administration through preventing first pass metabolism and boosting patient compliance [7] When Transdermal Scope was established in 1980, it included the drug Scopolamine to alleviate motion sickness. It is a membrane-moderated system, the transdermal device. The membrane within this technology is made of a polypropylene microporous sheet. The supply of drugs is created by dissolving the medication in a blend of polyisobutylene and mineral oil. This research release occurs available for 3 days at a time.[8]

Transdermal medication delivery system type :

1. Adhesive System Drug with One Layer:

They kind of film has an clinging layer that includes the medication. Furthermore to securing the many layers and the system as a whole to the skin, The layer of glue is in charge of releasing the medication. Both a temporary and permanent liner encircle the adhesive layer.

2. System of Reservoirs:

The medication is kept in the reservoir of this system, which is encircled by a backing layer as well as a membrane that regulates flow rate. Additionally, a membrane with a microporous rate allows the medication to be discharge command. The medication may be distributed through a gel, suspension, solution, solid polymer matrix, or reservoir section.

The matrix system there are two types of this system:

A. Substance within the matrix framework :

The medication is first scattered in the polymer that sticks. The polymer adhesive with medication is next spread either melting or solvent casting the glue over an impermeable supporting layer in the case of hot-melt adhesives, therefore forming

B. System of Matrix Dispersion:

They technique disperses the medication consistently using a matrix of hydrophilic or lipophilic polymers. This also comprises polymer, in addition The medicine is secured atop an occlusive foundation plate within a medication-resistant support stratum compartment. They method distributes the sticky around the edge of the drug reservoir rather than apply.

C. Micro-Reservoir System:

It is uniformly dispersing Its Storage systems and matrix-dispersion are combined in this system. This technique produces millions of impermeable, microscopic drug reservoir spheres By putting an end to the medication in a watery mixture of a lipophilic polymeric that is soluble in water.^[10,11,12]

Transdermal patch

An adhesive patch with medication applied to it and placed to the skin in order for a recommended dosage of medicine to enter the bloodstream via the skin is called a transdermal patch. When medication input is no longer desired, this technology allows the drug therapy to be discontinued immediately. The technique makes it possible to reduce dosage frequency, which is particularly beneficial for a substance having a brief half-life in biology. The basic function of human skin affects transdermal medication delivery, hence posing restrictions. Many Drugs can be applied topically. As an example, the transdermal technique is presently utilized for patches containing scopolamine to prevent motion sickness and fentanyl patches for chronic pain syndromes or cancer pain management^[13,14]

Advantages of transdermal patches

- Enhanced systemic bioavailability due to leaving out of the first hepatic metabolism.
- Give a continuous pharmacological infusion for an extended period of time.
- no disruption of the intestinal and stomach juices.
- Because the streamlined drug schedule is non-invasive, painless, and easy to use, it improves patient compliance and comfort.
- Action duration lengthens and becomes predictable.
- Handling and application ease.
- When patients are unconscious or sick, it is a huge benefit.
- steady medication penetration via the skin that maintains constant plasma levels while remaining non-invasive.
- Medication therapy is a quickly ceased by taking the application off of the skin's exterior.
- Transdermal distribution can be a useful option for medications that upset the stomach because it doesn't directly affect the stomach or intestines.
- By preventing both intra- and inter-individual variance, it can improve the effectiveness of treatment.
- Transdermal patches are easily removed from the skin in the event of poisoning.

- less frequent dosage because to the prolonged action.
- There have been transdermal patches helpful within creating fresh uses for currently available medicinal.
- For those who find it difficult to take their medication orally, this is an alternate method^[15,16]

Disadvantage of transdermal patches

- The use transdermal delivery could not be cost-effective.
- It is unable to produce high blood or plasma drug levels.
- Since skin is impermeable, only strong API can be injected with this method due to drug entrance barriers.
- It is difficult for drugs with big molecular sizes to be absorbed.
- Ionic medications create problems.
- Delivering a high dose More than 10 milligrams daily can be difficult.
- Medications with high or extremely low partition coefficients are unable to go into the bloodstream^[17,18]



Fig 2: Transdermal Patch on Skin

Transdermal device type

Adhesive patches with drugs:

This type of dose format acts as a depot for medicine replacement and is made of polymer with sticky properties. On the other hand, backing laminate is positioned above polymeric liner, which serves in order to assist prescription drugs depot

Transdermal vapor patches:

They're made of polymer sticky layers qualities that have release of vapor characteristics, allowing fumes to be released after being seen. These films typically include flammable oils. non-invasive additionally painless, to prevent gastrointestinal (GI).

Membrane moderated transdermal reservoir patches:

The drug release rate in these kinds of systems regulates the the publication of the pharmaceuticals via a permeable polymeric cell membrane. Typically, a transdermal prescription drugs delivery device with membrane moderation has a drug reservoir with an impermeable layer of plastic or metal serving as a backing membrane, and embedded in porous polymer^[19,20]

Formation of transdermal patch

DRUG:

A drug has to possess favorable physicochemical characteristics. A drug should be strong, non-irritating, have a low melting point, a short half-life, a low molecular weight (up to 1000 Dalton), and an affinity for both lipophilic and hydrophilic substances.[21]

Table No:1

Sr no.	Measurement	Effects
1.	Quantity	Must be small
2.	Duration of half a life in hours	10 or lower is the ideal number.
3.	Molecular mass	It ought to be lower than 500.
4.	Dividend per unit	Log P (water and octanol in the -1 to 3)
5.	The Skin permeability coefficient	Not to exceed 0.5×10^{-3} cm/h
6.	Cutaneous response	It ought not to irritate
7.	Bioavailability of oral	Must be tiny
8.	Index of therapeutics	Must be small
9.	Focus	Moment
10.	pH of saturation solubility in water	5 to 9
11.	Quantity delivered	Less than 20 mg daily

Supporting layer: It allows printing, shields the patch that was taken from the outside world, and offers assistance.

Polymer: The primary component within the system that establishes and regulates the loading of drugs, drug release rate, and appropriate patch adherence to the skin is made of polymer.

Polymer controls the medication's release from the device:

Table:2

Organic polymers	Artificial polymers	Artificial polymers
Waxes, Gelatin, and Zein, Natural Rubber, Gummi, Zein derivatives, and glucose	For example, nitrile, acrylonitrile, silicone rubber, polybutadiene, Hydrinerubber, polysiloxane, butyl rubber, styrene butadiene, Neoprene, etc.	Polypropylene and Polyethylene, Epoxy, Polyurea, Polyvinylpyrrolidone, Polyamide, Polyacrylate, and so forth.

1. Permeation Enhancers:

Agents known as penetration enhancers or promoters can transfer the absorption of medications from medication delivery mechanisms to the skin without having any direct therapeutic effects.

The flow, of medicines throughout the skin can be stated as.

J equals $D \frac{dC}{dx}$

When C is the diffusing species' concentration, X is the spatial synchronize, and D is the diffusion coefficient, which is influenced by the membrane resistance as well as the diffusing molecule's size, shape, and flexibility.

Even if the response for J using an alternative membrane heterogeneities and boundary conditions able to highly complex, the following equation can be used to determine the basic ideas of flux enhancement. At first, the concentration gradient is thermodynamic^[22,23]

2. Backing Laminate:

It is a supportive material that resists permeability-inducing agents and drugs alike. They need to be compatible chemically with the medication, adhesive as well as additional excipients. ex: Polyester, Record vinyl, and films made of polyethylene^[24]

Other excipient

Adhesives:

Far, pressure-sensitive adhesive has been used to complete the transdermal device's skin attachment. The pressure Thus - Sensitive sticky is applied to The face of the device or inside its return, expanding outwards from there.

Release Liner:

Release liner stops contamination and drug loss during storage by preventing migration of the drug into the sticky layer. Thus, it is thought of is a part of the best packaging supplies as opposed to the drug's dose form. The composition of the release liner comprises a base layer composed of either non- occlude material (fabric (paper) or occlusive material

(vinyl chloride, polyethylene), as well as a layer of coating composed either Teflon or silicon. Additional components utilized for the TDDS release liner consist of metalized laminate and polyester foil^[25]

Surfactants :

It is suggested that these substances improve the transport of hydrophilic medicines along polar pathways. A surfactant's ability to alter penetration depends on its length of the hydrocarbon chain and head group. Since certain substances irritate the skin, it is necessary to strike a harmony between irritation and improvement of penetration. Anionic surfactants have a significant ability to permeate and engage in skin interaction. These polymers can cause significant alterations once they've entered the skin. It is said that cationic surfactants cause more irritation than anionic surfactants, and as skin penetration

enhancers, they are no longer extensively researched. The nonionic surfactant class, out of the three basic classes, is well-studied and has a reputation for having the least irritability.^[26]

II. PREPARATION OF TRANSDERMAL PATCHES

Mercury substrate method:

Plasticizer and polymer solution are added to the medication to dissolve it. After agitating five to fifteen minutes at a time to create a uniform dispersal, it is poured into an inverted funnel placed on top of a flat mercury surface to prevent solvent evaporation (Wiechers 1992). In a 2006 study, Rathore et al. investigated the fabrication of sulfate transdermal matrix patches utilizing ethyl cellulose and cellulose acetate polymer. Solvent casting was used to create the transdermal sulphate patches using a mercury substrate. Several polymeric transdermal patches containing sulfate were made for the current study. Studies were conducted to determine how permeability enhancers affected the drug's permeability via patches made of ethyl cellulose and cellulose acetate. The polyblend demonstrated excellent filmmaking qualities, as well as the casting technique.^[27,28]

Method of Asymmetric TPX Membrane:

This finding was made in 1994 by John and Berner. Initial patches able to be made with this method by utilizing Polyester film that is heat-sealable (type 1009, 3M) accompanied by a backing membrane that is concave and features a diameter of 1 cm. The medication is spread across a concave membrane after being coated utilizing a poly(4-methyl-1-pentene) asymmetric TPX membrane, which is then glued with glue. Either the damp or the dry reversal process is accustomed to make them. TPX is dissolved in this 60 °C with a blend of non-soluble ingredients and the solvent cyclohexane to create a solution of polymers. For a full day, 40°C is maintained for the polymer solution before being assembled onto a dish made of glass. Following 30 seconds of evaporation of the glass plate and the casting film at 50°C needs to be a steady 25°C temperature. After soaking for 10 minutes the membrane is removable and left to dry by air in a 50°C oven for circulation for 12 hours.^[29]

“EVAC membranes” method:

Rate control membranes such as Membranes made of polyethylene (PE), reservoir gel made of 1% carbopol, and ethylene vinyl acetate copolymer (EVAC). can be utilized to set up the goal transdermal treatment system. Propylene glycol is utilized in the event that the drug is not water soluble for the getting the gel ready. The medication dissolves in propylene glycol, forming carbopol resin is subsequently included in the concoction and neutralized utilizing a sodium hydroxide solution of 5% w/w. The drug (in the gel state) is put in a sheet of support material that covers the designated region. In order to make a watertight gadget mechanism that controls the Gel is going to be covered with a membrane, and to seal, the edges will be heated. Friends et al. (1991) investigated the irritability of levonorgestrel applied topically delivery systems^[30]

Teflon Circular Mold Technique:

Baker and Heller made the discovery in 1989. Polymer solutions in different ratios are utilized as a solvent for organic materials. Next, the solution is split into two halves. One component is filled with the specified dosage of medication, while the other is filled with varying concentrations of enhancers. The two sections are then mixed together. Next, a plasticizer (such as di-n-butylphthalate) is added to the medication's polymer solution. Before the material is filled a Teflon

mold. shaped like a circle, it must be well mixed for 12 hours. The molds need to be situated on a level platform and layered with an reversed funnel in order to regulate the vaporization of solvents in a model of a laminar flow hood at 0.5 m/s air speed. A day is twenty-four^[31,32]

Method of free film:

Putting on a mercury surface produces a free cellulose acetate film. Chloroform, an organic solvent, is accustomed to produce a 2% w/w polymer solution, for example. The polymer solution is mixed with the plasticizer at the desired concentration (for example, 40% w/w of weight of polymers). A glass petri dish with a glass ring set over the surface of the mercury is filled with a small volume (5 ml) of polymer solution. Covering the petri dish with the funnel upside down controls The rate at which the the solvable. When The mercury surface is totally vaporized, and the solvent is examined to determine the structure of the film. The inside of a desiccator dried patch is removed and maintained in between the sheets of wax paper until needed^[33]

Method of solvent casting:

Transdermal patches were used made via the casting with solvent procedure. In addition to polyethylene glycol 400 acting as a plasticizer, oleic acid and propylene glycol were employed to improve permeability. We then assessed the mechanical and physicochemical properties of the newly developed patche.




Fig 3: Method of solvent casting

By Using IPM Membranes method:

Using a magnetic stirrer, Drug dissolution occurs in a solution between water and propylene glycol that contains polymers carbon 940, as well as the combination is agitated for 12 hours. Triethanol amine is to be included into the mixture in order to make it viscous and neutralize it. If the medication has a extremely low solubility in a liquid state, solution gel can be obtained by using buffer pH 7.4. The substance that has developed can incorporate itself into the IPM membrane^[34]

Glass Substrate technique :

Following the expansion of the polymeric solutions, the required quantity plasticizer, as well as medication solution are included, and everything is mixed for 10 minutes. In order to remove any trapped air, it is further put alone for a time before being poured into a dry, clean Petri plate. To control the solvent evaporation rate, place A funnel made of glass upside-down above the Petri dish. The parched patch are taken out and retained within a drying device over night^[35]

Method of evaporating solvents :

In solvent evaporation, a Polymer is emulsified In a aqueous phase and then dispersed in a volatile solvent, such as ethyl acetate, dichloromethane, or chloroform. The solvent is then continuously stirred, heated to a high temperature, or evaporated using a vacuum.

Evaluation of transdermal patch:

1. **Drug content determination:** After breaking the transdermal patch, it is dissolved in solvent to evaluate the drug content. A particular analytical technique is then used to measure the amount of drug present in the filtrate.^[36]
2. **Weight Uniformity:** Prior to examination, the created Patches need to dry for four hours at 60 °C. a particular repair section needs to be separated into several sections and measured with an electronic balance. The average weight and standard deviation figures are derived from the individual weights. must as determined^[37]
3. **Patch Thickness:** The goal of this patch is to keep transdermal compositions consistent. It is ascertained by using a micrometer to measure the patch's thickness three times^[38]
4. **Folding Endurance:** Assessing the folding durability of films that are frequently folded under harsh conditions entails figuring out their folding capacity. The film is simultaneously folded spot repeatedly until it cracks to assess The collapsible endurance. The quantity of The folding endurance value () is The quantity of times the films could be gathered up in identical direction without fracturing^[39]
5. **Content of Moisture:** The transdermal patch's moisture loss after being stored in a desiccator can be used to compute this value. Balanced and stored within desiccators, the patch calcium chloride for a full day after which the ultimate The transdermal patch's weight is established. It is stated as a percentage: % (Initial Mass - Final Mass) / Initial Moisture Content mass times 100^[40]
6. **Absorption of Moisture:** It is necessary to store the weighing films in desiccators filled with saturated potassium chloride solutions. that allow you to maintain a RH of 84% for 24 hours at room temperature The films need to be weighed again in a day in order to determine the percentage of apply the following formula to moisture uptake. [Final Weight-Foreign Weight/First Weight] × 100 = percent humidity uptake.^[41, 42]
7. **Flatness:** A transdermal patch should not tighten over time and have a smooth surface. The study of flatness can be used to illustrate this. Two strips are cut from each side of the patches and one from the center to determine the flatness of the patches. Every strip's length is measured and the % constriction is used to measure the variance in length. One hundred percent flatness is equal to zero percent constriction^[43]
8. **Flexural Strength:** The film's The tensile strength was ascertained utilizing a typical strength testing The upper is moveable and the lower is fixed. A 4-by-1-centimeter test film is placed between these cell grips, and pressure is exerted
9. gradually till the end of the patch. (30) The reading on the dial in kg is immediately used to determine the film's elasticity power. This is how The tensile strength is given. Tensile power is equal to cross sectional area / tensile load at break.
10. **Water vapour transmission studies (WVT):** There contains one gram of calcium chloride into empty, already dried vials with similar diameters to estimate WVT. Using an adhesive such as silicon adhesive grease, The films made of polymers are adhered to the top and then Let it sit for five min. We weigh the vials precisely and put in a humidifier with a 68% relative humidity. Subsequently, the vials undergo repeated weighing for a period of seven days, with an increase in mass being interpreted as a numerical indicator of the amount of humidity transferred via the patch^[44]
11. **Stability Studies:** The patch is kept at 75 ± 5% relative humidity and 40 ± 0.5 °C. to ensure stability. Drug analysis is performed on samples throughout keeping things for 0, 30, 60, 90, and 180 days at a time. material to provide insight into the stability of the product^[45]
12. **Swellability:** To measure this transdermal patch property, place a Petri dish with a known weight filled utilizing 50 mL of 7.4 pH phosphate buffer. The instance absorbs over the course of around 30 minutes.
13. **Skin irritation study:** Sensitization and irritation of the skin Healthy bunnies (typical weight of 1.2 to 1.5 kg) can be checked out. The rabbit's dorsal surface (50 cm²) should be well cleaned. The hair should be

eliminated by shaving the clean surface, and the surface can then be cleansed with rectified spirit and representative formulas used to formulas used the dermis. Following a day, the repair is taken off. and depending on the degree of skin damage, the skin must be examined and graded into five categories^[46]

Studies on drug release in vitro:

The manufactured patches' medication release can be evaluated using the USP, or paddle over disk method equipment V). Films without moisture of a known The required The thickness is precisely shaped, measured, then placed on a glass dish. using an sticky . After The device was equilibrated The glass plate was immersed in 500 ml of water to 32±0.5°C. milliliters of the pH 7.4 phosphate buffer or dissolving medium. At a speed of 50 revolutions per minute, the paddle was then adjusted to be 2.5 centimeters from the plate of glass. Five milliliter aliquots of Samples may be removed at the proper times lasting up to a whole day, and high-performance liquid chromatography (HPLC) or a UV spectrophotometer can be used for analysis. It is necessary to carry out the test^[47]

Studies on Ex vivo Permeation

Animal biological membranes, such as the skin of a rat or pig's ear, divide the giver and acceptor sections of the Diffusion cell Franz. The acceptor section normally contains phosphate pH 7.4 buffer, a suitable magnetic stirrin supply, and ambient temperature control set at 37 ± 0.5°C.^[48]

1. Animal models: Small-scale animal studies are chosen over human studies because they don't take as much time or money. The most frequently employed animal species in transdermal medication administration technique evaluations are rhesus, dog, and hairless rat, and rabbit, guinea pig, and mouse, monkey, etc. The current body of research indicates that in vivo as well as in vitro settings, hairless animals are favored over hairy animals.^[49]

2. Human models: Following the patch is applied In terms of human volunteers, the final phase of a For the development of a transdermal device, pharmacokinetic and pharmacodynamic information. Clinical trials are conducted in order to assess transdermal systems, such as the effectiveness, associated risk, adverse reactions, and patient adherence. Phase-II clinical studies evaluate the Temporary security and primary efficacy in individuals, while stage-II clinical trials primarily assess security in volunteers. Phase-III studies demonstrate the safety and efficacy in a sizable patient population, while phase-IV studies are conducted for marketed patches as part of post-marketing surveillance to identify adverse medication reactions. Even though they need a lot of money, human studies are the most effective way to evaluate a drug's effectiveness^[50,51]

Marketed Products:

Table: 3

Name of Brand	Ingredients that are active	Advantage	The manufacturer
ANICORDERM	Nicotine	Giving up puffing	Glaxo Smith Kline
TESTODERM	Testimonials	Low testosterone levels	Mountain View, Alza,
LICODEM	Lido de cane	Pain from Herpes related neuralgia	Endo Inc.
HYTROTROL	Butylene	Hyperactivity of the bladder	Wharton Pharmaceutical
EMASAN	Butrylene	Severe sadness	Squibb Myers-Bristol
TRADERMSCOP	Scopol amine use	Shaky movement	Consumer Health The Novartis
TRADERMNITRO	Nevi glycerin	Pectorile angina	The Novartis
TATS-CATASPRESS	Synthroid	High blood pressure	Engelheim Boehringer
ESTRADOR	Estrazol	Indications of menopause	The Novartis

Adverse events :

The FDA declared in 2005 that it was looking into reports of fatalities and other severe side effects associated with overdose on opioids in patients taking Prolonged use of, a transdermal layer containing fentanyl, for suffering relief. Later, in June 2005, the The label of a Duragesic product was revised to include safety data^[52]

The makers of the Daily Transcript ADHD patch, Shire and Novena Pharmaceuticals, declared a voluntary remembrance of multiple large portions within the patch in 2007 because of issues releasing the liner patch from its release for protection. Ever since, there have been No reports of any additionally issues either in its protective container or with the patch^[53]

A production flaw that permitted the gel to contain the drug to prematurely seep out of its sack led to a recall of the fentanyl patch in 2008 by two manufacturers: Sandoz and ALZA Pharmacies, an affiliate of large Johnson, a maker of medical devices & Johnson. This could have resulted in an overdose or even death^[54]

Transdermal medication patches with metallic backings have the potential to cause burns during MRI scans, according to a 2009 public health advice issued by the FDA. It is recommended that patients take off any medicated patches before having an MRI and replace them with fresh ones when the scan is finished^[55]

III. CONCLUSION

Drug delivery via TDD devices has proven to be non-toxic, effective, painless, and patient-complies. The creation of a reliable method for NSAID transdermal delivery could boost concentrations of local soft tissue and joints, as well as lessens the adverse effects of oral administration. A range of NSAID medications can be used to treat different types of skin conditions, But still not all NSAIDs can be administered in this way due to their biochemical characteristics, that are crucial Regarding the administration of transdermal medications. Consequently, in the case of NSAIDs, it is necessary to investigate the possibilities of this administration method.^[56,57]

REFERENCES

- [1]. Namdeo A; Garud N; Guard A. Int. J. Drug Delivery, 2012, 4,470-476.
- [2]. Verma P; Thakur AS; Deshmukh K; Dr.Jha AK; Verma S. Int. J. Pharm. Study & Res., 2010, 1, 54-59
- [3]. Vandana Yadav, Sipia Altaf Bhai M, Mamatha Y, Prashant VV (2012) Transdermal Drug Delivery System: A Technical Writeup. Journal of Pharmaceutical & Scientific innovation .
- [4]. P K Gaur, S Mishra, S Purohit, K Dave (2009) Transdermal Drug Delivery System: A Review. Asian Journal of Pharmaceutical and Clinical Research 14-20.
- [5]. Mzrieh EN. Human anatomy and physiology. 6th edition, India, Dorling Kindersley Pvt.Ltd, 2006; 152-15
- [6]. Freedberg IM, Eisen AZ, Wolf K, Austen KF, Goldsmith LA, Katz SI. Fitzpatrick's dermatology in general
- [7]. medicine, 6th edition, Vol-1, Mc Graw-Hill Medical publishing division, 2003; 58-85
- [8]. Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal patches: History, development and pharmacology. British Journal of Pharmacology. 2015. 2015 May;172(9):2179-2209
- [9]. Reddy YK; Reddy DM; Kumar MA. Indian J. Res. Pharm. Biotechnol., 2014, 1094-110
- [10]. Shingade GM; Quazi A; Sabale PM; Grampurohit ND; Gadhave MV; Jadhav SL; Gaikwad DD. J. dru delivery Ther. 2012, 66-75.
- [11]. Chowdary K.P.R and Naidu R.A.S, Transdermal Drug Delivery, A Review of Current Status, Indian Drugs, 1995; 32: 414- 422 .
- [12]. Saurabh Pandey, Ashutosh Badola, Ganesh Kumar Bhatt, Preeti Kothiyal (2013) An Overview on Transdermal Drug Delivery System. International Journal of Pharmaceutical and Chemical sciences 2(3).
- [13]. P K Gaur, S Mishra, S Purohit, K Dave (2009) Transdermal Drug Delivery System: A Review. Asian Journal of Pharmaceutical and Clinical Research 2(1): 14-20.
- [14]. Dhiman S; Thakur GS; Rehni AK. Int. J. Pharm. Pharm. Sci., 2011, 3(5), 26-34
- [15]. Shingade GM; Quazi A; Sabale PM; Grampurohit ND; Gadhave MV; Jadhav SL; Gaikwad DD. J. drugdelivery Ther. 2012, 2(1), 66-75
- [16]. Dhiman S; Thakur GS; Rehni AK. Int. J. Pharm. Pharm. Sci., 2011, 3(5), 26-34.

- [17]. Sun L, Cun D, Yuan B, Cui H, Xi H, Mu L, et al. Formulation and in vitro/in vivo correlation of a drug-in-adhesive transdermal patch containing azasetron. *Journal of Pharmaceutical Sciences*. 2012 Dec;101(12):4540-4548.
- [18]. Raghuraman V, Pandey VP. Approaches And Significance Of Transdermal Drug Delivery Systems: A Review. *International Journal Of Pharmaceutical Sciences And Research*. 2014 Feb;5(2):340–345.
- [19]. Sandhu P; Bilandi A; Kataria S; Middha A. *Int. J. Res. Pharm. Chem*. 2011, 1(40), 1139-1151.
- [20]. Sugibayashi K; Morimoto Y. *J. controlled Release*, 1994, 29, 177-185.
- [21]. Arora A; Prausnitz MR; Mitragotri S. *Int. J. Pharm.*, 2008, 364, 227-236
- [22]. Hemangi J, Patel, Jitendra S, Patel, Keyur D, Patel, *Transdermal Patch for Ketotifen Fumarate as Asthmatic Drug, IJPR*, 2009; 1(1): 1297-1304
- [23]. Shalu Rani, Kamal Saroha, Navneet Syan, *Transdermal Patches a successful tool in Transdermal Drug Delivery System: An overview, Der Pharmacia Sinica*, 2011; 2(5): 17-29.
- [24]. K Ezhumalai, P Ilavarasan, R Murali Mugundhan, U Sathiyaraj, AN Rajalakshmi (2011) *Transdermal Patches in Novel Drug Delivery System. International Journal of Pharmacy & Technology* 3(2): 2402- 2419.
- [25]. Chowdary K.PR and Naidu R.A.S, *Preparation and Evaluation of Cellulose Acetate Films as Rate Controlling Membranes for Transdermal use, Indian Drugs*, 1991; 29(7): 312-315.
- [26]. Azhar Ahmed, Nirmal Karki, Rita Charde, Manoj Charde, Bhushan Gandhare, *Transdermal Drug Delivery Systems, An overview, International Journal of Biomedical and Advance Research*, 2011; 02(01): 38-56.
- [27]. Jeans CW, Heard CM, *A therapeutic dose of primaquine can be delivered across excise human skin from simple transdermal patches, Int J Pharm*, 1999,189(1),1-6.
- [28]. Xi H, Yang Y, Zhao D, et al. *Transdermal patches for site-specific delivery of anastrozole: In vitro and local tissue disposition evaluation, Int J Pharm*, 2010,391(1 2),73-78
- [29]. Willams AC, Barry BW, *Penetration Enhancers, Adv Drug Del Rev*, 2004, 56, 603-618.
- [30]. Tsai JC, Guy RH, Thornfeldt CR, Gao WN, Feingold KR, Elias PM, *Metabolic*
- [31]. *Approaches to Enhance Transdermal drug delivery, J Pharm Sci*, 1998, 85,643-648
- [32]. Nikhil Sharma, Bharat Parashar, Shalini Sharma, Uday Mahajan (2012) *Blooming Pharma Industry with Transdermal Drug Delivery System. Indo Global Journal of Pharmaceutical Sciences* 2(3): 262-278.
- [33]. Nikhil Sharma, Bharat Parashar, Shalini Sharma, Uday Mahajan (2012) *Blooming Pharma Industry with Transdermal Drug Delivery System. Indo Global Journal of Pharmaceutical Sciences* 2(3): 262-278 .
- [34]. Kalantaridou SN, Calis KA, Mazer NA, Godoy H, Nelson LM, *A pilot study of an investigational testosterone transdermal patch system in young women with premature ovarian failure, J Clin Endocrinol Metab*, 2005,90(12),6549-52.
- [35]. Dhiman Sonia (2011) *Transdermal Patches: A Recent Approach To New Drug Delivery System. International Journal of Pharmacy and Pharm* 3(5).
- [36]. Levin G, Gershonowitz A, Sacks H, Stern M, Sherman A, Rudaev S, Zivin I, Phillip M, *Transdermal delivery of human growth hormone through RF-microchannels, PharmRes*, 2005,22(4),550-5.
- [37]. Priya JK, Kumar PP, Begum SKS. *Formulation and evaluation of clopidogrel bisulphate transdermal patches using vegetable oils as permeation enhancer. International Journal Of Pharmaceutical Sciences And Research*. 2014 Feb;5(2):473–482.
- [38]. Mutalik, N, Udupa, *Glibenclamide Transdermal Patches, Physicochemical, Pharmacodynamic and Pharmacokinetic Evaluations, Journal of Pharmaceutical Sciences*, 2004; 93(6): 1557-1594.
- [39]. Mohammadpoor SA, Akbari S, Sadrjehani M, Nourpanah P. *Fabrication of electrospun ibuprofen-loaded poly(vinyl alcohol)/ hyper-branched poly(ethylenimine) fibers and their release behaviors. Journal of biomaterials science-polymer edition*. 2020 Jan;31(2):261–275.
- [40]. Costa P, Ferreria DC, Morgado R, Sousa Lobo JM, *Design and evaluation of alorazepam transdermal delivery system, Drug Dev Ind Pharm*, 1997,23,939-944.
- [41]. Priyanka Arora, Biswajit Mukherjee, *Design Development Physicochemical and in-vitro Evaluation of Transdermal Patches Containing Diclofenac Diethylammonium Salt, Journal of Pharmaceutical Sciences*, 2002; 91(9): 2076-2089.

- [42]. Koteswar K.B, Udupa N and Vasantha Kumar, Design and Evaluation of Captopril Transdermal Preparations, *Indian Drugs*, 15(29): 680-685
- [43]. Baker W and Heller J, Material Selection for Transdermal Delivery Syste Transdermal Drug Delivery: Developmental Issues and Research Initiatives, J. Hadgraft and Eds. Marcel Dekker, Inc., New York 1989;293-311.
- [44]. Yuveraj Singh Tanwar, Chetan Singh Chauhan, Anshu Sharma, Development and Evaluation of Carvidilol Transdermal Patches, *Acta Pharm*, 2007; 57: 151–159.
- [45]. Katz NP, Gammaitoni AR, Davis MW, Dworkin RH, Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial, *Pain Med*, 2002,3(4),324-32.
- [46]. Prabu SL, Shirwaikar AA, Shirwaikar A, Kumar A, Jacob A. Design and Evaluation of Matrix Diffusion Controlled Transdermal Patches of Diltiazem Hydrochloride. *ARS Pharmaceutica*. 2008;49(3):211–217
- [47]. Pravin Gavali, Atul, Gaikwad, Radhika P.R, Sivakumar T, Design and Development of Hydroxypropyl Methylcellulose based polymeric film of Enalapril Maleate, *International Journal Of Pharmtech Research*, 2010; 2(1): 274-282.
- [48]. Koteswar K.B, Udupa N and Vasantha Kumar, Design and Evaluation of Captopril Transdermal Preparations, *Indian Drugs*, 15(29): 680-685.
- [49]. Zanela da Silva Marques T, Santos-Oliveira R, De Siqueira LB de O, Da Silva Cardoso V, De Freitas ZMF, Da Silva Ascensão Barros RDC, et al. Development and characterization of a nanoemulsion containing propranolol for topical delivery. *International Journal of Nanomedicine*. 2018 May 14;13: 2827-2837.
- [50]. Walker M, Dugard PH, Scott RC, In vitro percutaneous absorption studies: a comparison of human and laboratory species, *Hum Toxicol*, 1983,2,561–562.
- [51]. Wester RC, Maibach HI, Percutaneous absorption: Neonate compared with adult, In: Hunt MKD, ed, *Environmental factors in human growth and development*, Cold Spring Harbor, New York, Cold Spring Harbor Press 1982, 3-15
- [52]. Walker M, Dugard PH, Scott RC, In vitro percutaneous absorption studies: a comparison of human and laboratory species, *Hum Toxicol*, 1983,2,561–562.
- [53]. FDA ALERT (07/2005): "Narcotic Overdose and Death". Food and Drug Administration. 2005-07-15. Archived from the original on 2007-02-20. Retrieved 2007-02-24.
- [54]. Megget, Katrina (2007-09-05). "ADHD Transdermal Patches Withdrawn". Retrieved 2010-09-28.
- [55]. Silverman, Ed (2008-02-12). "J&J and Sandoz Recall Fentanyl Patches". Retrieved 2010-09-28.
- [56]. "FDA Public Health Advisory: Risk of Burns during MRI Scans from Transdermal Drug Patches with Metallic Backings". Food and Drug Administration. Archived from the original on March 7, 2009. Retrieved March 9, 2009 .
- [57]. Jones P, Lamdin R, Dalziel SR. Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. *Cochrane Database Syst Rev* 2020;8:CD007789.
- [58]. Gyöngyösi A, Verner V, Bereczki I, Kiss-Szikszai A, Zilinyi R, Tószaki A, et al. Basic pharmacological characterization of EV-34, a New H₂S-releasing ibuprofen derivative. *Molecules* 2021;26:599.